We provide a progressive, flexible work environment and a highly competitive total rewards program designed to meet your work/life needs now and in the future. In our product, our pipeline and in our supportive culture, Cubist demonstrates its continuing commitment of excellence to our employees and our shareholders.
CUBICIN® (daptomycin for injection) has been used in the treatment of more than 750,000 patients with serious and sometimes life-threatening infections. Since we began selling CUBICIN in November 2003, it has experienced the most successful I.V. antibiotic launch, in dollar terms, in U.S. history. Our financial success in 2008 resulted in Cubist being named to the number one position in The Boston Globe’s 21st annual “Globe 100” listing. Also, our employees’ feedback placed us 13th in the mid-size company list of the The Boston Globe “100’s Top Places to Work” in 2008.
